UM-164 | Interleukin Related interleukin-related.com

Product Name :
UM-164

Search keywords :
UM-164

drugId :
null

Target Vo:
Tyrosine-protein kinase SRC

Target Vo Short Name :
SRC

Moa_Name:
Tyrosine-protein kinase SRC inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
University Of Michigan

Active Company_Name :
University Of Michigan

Active Indication_Name:
Triple Negative Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
cIAP2 (YP5071) Mouse mAb Autophagy
p38 alpha/MAPK14 Antibody In Vivo
RANKL/CD254 Antibody: RANKL/CD254 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL/CD254 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, dog background without labeling.

Author: Interleukin Related

Related Posts